Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-01-04
2005-01-04
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252160, C514S260100, C514S301000, C544S117000, C544S118000, C544S278000, C546S114000
Reexamination Certificate
active
06838457
ABSTRACT:
The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.
REFERENCES:
patent: 3661908 (1972-05-01), Woitun et al.
patent: 3808211 (1974-04-01), Benjamin
patent: 3830813 (1974-08-01), Woitun et al.
patent: 5304554 (1994-04-01), Strekowski et al.
patent: 5990177 (1999-11-01), Brown
patent: 276057 (1988-07-01), None
patent: 0 655 456 (1995-05-01), None
patent: 0882717 (1998-12-01), None
patent: 1067123 (2001-01-01), None
patent: 2295387 (1996-05-01), None
patent: 58-172379 (1983-10-01), None
patent: 1087492 (1988-04-01), None
patent: 10-175977 (1998-06-01), None
patent: 11-209287 (1999-08-01), None
patent: WO 9823613 (1998-06-01), None
patent: WO 9943682 (1999-09-01), None
patent: WO 0181346 (2001-11-01), None
Bourguignon et al., CAPLUS Abstract 83:114329, 1975.*
Berrie, PubMed Abstract (Expert Opini.Investig. Drugs 10(6):1085-98), 2001.
Bi et al., “Proliferative defect and embryonic lethality [ . . ]”,J. Biol. Chem., (1999), 274, 10963-8.
Di Cristofano, et al., “Pten is essential for embryonic development and tumor suppression”, Nat. Genetics (1998), 19, 348-55.
Maehama et al., “The Tumor Suppressor[ . . . ]”, J. Biol. Chem., (1998), 273, 13375-13378.
Merino et al., “Synthesis and Anti-HIV activities of new pyrimido[5,4-b] indoles”, vol. 54, No. 4, 255-264.
Misawa et al., PubMed Abstract (Biochem. Biophys. Res. Commun. 244(2):531-9), 1998.
Nishigaki et al., “Synthetic Antibacterials. [ . . ]”.J. Med. Chem., (1972), 15, 7, 713-4.
Osselaere et al., Chem. Abstracts, (1975), 83:9770n.
Pienador et al., (1992), “A convenient synthesis for some new pyrodol[ . . ]”,J. Heterocycl. Chem. (1992), 29(7), 1693-702.
Sangapure et al., Chem. Abstract 134:20777, Indian J. of Heterocyclic Chem., (2000).
Hayakawa Masahiko
Kaizawa Hiroyuki
Kawaguchi Ken-Ichi
Koizumi Tomonobu
Matsuda Koyo
Fulbright & Jaworski L.L.P.
Imperial Cancer Research Technology Ltd.
Ludwig Institute for Cancer Research
Rao Deepak
Yamanouchi Pharmaceutical Co. Ltd.
LandOfFree
Fused heteroaryl derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused heteroaryl derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused heteroaryl derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3432270